VA-REGULA
6.8.2024 08:01:33 CEST | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, has released new findings from its study “The New Imperative: Digital IDs,” which unveil how companies worldwide assess their revenue transformation after digital ID implementation. These findings also highlight the use cases where the digital ID adoption will have the most notable effect.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805603877/en/
Regula's study uncovers how companies globally evaluate revenue transformation post-digital ID implementation, with an overwhelmingly positive outlook. (Graphic: Regula)
Forrester Consulting, commissioned by Regula to conduct “The New Imperative: Digital IDs” study, underlines that most respondents, 89%, anticipate a positive impact on revenue from the adoption of digital IDs. Specifically, 32% of businesses anticipate a 20%-29% rise in revenue, 23% foresee a 10%-19% increase, 16% predict a boost of over 30%, and 18% expect up to a 10% growth.
Interestingly, the Middle East seems to be more optimistic about adopting digital IDs. Only 4% of respondents in this region think that there will be no significant change in revenue, which is much lower than the global rate (10%) or the one in Europe, where 13% of businesses do not expect any change.
The most promising areas
“The New Imperative: Digital IDs” study indicates that the benefits from digital ID implementation will be most noticeable and yield the fastest results in the following top five use cases:
- online financial transactions (46% of respondents globally);
- online account opening (38%);
- eCommerce transactions (33%);
- eGovernment services (32%);
- remote customer onboarding (31%).
The Forrester Consulting study underlines: “These results highlight a significant expectation that digital IDs will enhance efficiency, security, and user experience in sectors where identity verification plays a crucial role in transaction security and customer trust.”
Regional Differences
For the region of North America, the most significant effect is expected to be experienced with online financial transactions (51%), online account opening (39%), remote customer onboarding (36%), and eCommerce transactions (35%). All of these rates are higher than the global. Interestingly, the region is rather more inclined to enhance age verification through digital IDs, with 21% expecting to see improvements in this use case (globally, this rate is 19%, and in the Middle East it is 14%).
In Europe, businesses share the global expectations. Thus, 44% anticipate seeing positive changes in online financial transactions, 38% – in online account opening, 36% – in eGovernment services, 30% – in remote customer onboarding, and 29% – in mobile device access. Europe seems to be more determined to improve eGovernment services: 36% of respondents here (compared to 32% globally) expect to benefit from adopting digital IDs.
In the Middle East, the study respondents express their expectations to see improvements in online financial transactions (44%) and online account opening (35%), though these rates are slightly lower than global. More than the other regions, the Middle East expects to see positive changes in workplace access and remote work (30%, compared to 25% global and 24% in Europe and North America), and healthcare services access (26% compared to 15% global and 9% in Europe).
“Businesses are shifting their approach to identity verification. Once merely a legal requirement or a commodity, it has now become a technological advancement and a strategic imperative. Our study shows that companies worldwide see the transformative potential of digital IDs to boost revenue, enhance security, and improve user experience. As we innovate and deliver advanced identity verification solutions, we are dedicated to helping businesses unlock these benefits and thrive in the digital era,” says Ihar Kliashchou, Chief Technology Officer at Regula.
If you are interested in getting more insights from the study, “The New Imperative: Digital IDs,” please download a complimentary copy from the Regula website.
Additional resources:
- 42% of companies globally are ready to implement Digital ID
- Digital IDs are not going to replace physical documents
- Regional expectations for digital ID fraud reduction
- EU Digital Identity Wallet: Exploring Its Current Potential
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805603877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
